Publications by authors named "J Y Bar"
Intrahepatic portosystemic shunt: salvage mechanism for oligohydramnios complicating fetal growth restriction.
Ultrasound Obstet Gynecol
January 2025
Objective: Portosystemic shunts in growth-restricted fetuses are more common than previously thought. We aimed to describe fetuses with growth restriction and transient oligohydramnios in which a congenital intrahepatic portosystemic shunt (CIPSS) was noted during follow-up.
Methods: This was a retrospective study of all fetuses diagnosed with growth restriction and transient oligohydramnios during a 5-year period in a large tertiary referral center.
Process models are increasingly used to support upstream process development in the biopharmaceutical industry for process optimization, scale-up and to reduce experimental effort. Parametric unstructured models based on biological mechanisms are highly promising, since they do not require large amounts of data. The critical part in the application is the certainty of the parameter estimates, since uncertainty of the parameter estimates propagates to model predictions and can increase the risk associated with those predictions.
View Article and Find Full Text PDFIntroduction: Chronic hand eczema (CHE) is a highly prevalent inflammatory skin condition which is often resistant to conventional treatments. Molecular insights of CHE remain limited. Tape stripping combined with high-throughput RNA sequencing can now provide a better insight into CHE pathogenesis in a minimally invasive fashion.
View Article and Find Full Text PDFSafety and Efficacy of Osimertinib in Patients With Non-Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis.
JCO Precis Oncol
November 2024
Article Synopsis
- A systematic review and meta-analysis were conducted to evaluate the safety and efficacy of osimertinib in non-small-cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor mutations.
- The analysis included 15 studies with 594 patients, revealing common mutations such as G719X and L861Q, and determining key metrics like a 51.30% objective response rate (ORR) and a median progression-free survival of 9.71 months.
- Osimertinib was found to be generally safe, with only 21.77% of patients experiencing serious adverse events, showing promise for treating NSCLC with these uncommon mutations.
Background: Real-world data regarding the use of dupilumab in children with atopic dermatitis (AD) are limited.
Objectives: To evaluate the real-world efficacy of dupilumab in children with moderate-to-severe AD over an extended follow-up period.
Methods: This was a retrospective study of patients (≤ 18 years) with moderate-to-severe AD treated with dupilumab in four Israeli tertiary centres.